Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
published : This week symbols : Nvsef save search
Viral Vector and Plasmid DNA Technologies: A Global Market Perspective
Published: 2024-04-17 (Crawled : 10:00) - prnewswire.com
TMO | News | $544.78 0.6% 0.0% 1.7M
|
Health Technology
|
| O: -0.26%
H: 0.03%
C: -1.55%
NVS | $94.36 1.93% 0.0% 2.3M
|
Health Technology
|
| O: 0.87%
H: 0.16%
C: -0.59%
RGNX | $15.67 -2.73% -2.87% 570K
|
Health Technology
|
| O: -1.43%
H: 2.27%
C: -3.18%
global dna market
Novartis Kesimpta® six-year efficacy data show substantial benefits in recently diagnosed treatment- naïve people with relapsing multiple sclerosis
Published: 2024-04-17 (Crawled : 06:00) - globenewswire.com
NVS | $94.36 1.93% 0.0% 2.3M
|
Health Technology
|
| O: 0.87%
H: 0.16%
C: -0.59%
kesimpta sclerosis novartis show benefits
Emphysema Treatment Market to Reach $8.7 Billion, Globally, by 2032 at 3.3% CAGR: Allied Market Research
Published: 2024-04-16 (Crawled : 14:00) - prnewswire.com
VTRS | $11.25 1.17% 1.16% 4.7M
|
Health Technology
|
| O: -0.53%
H: 0.0%
C: -1.24%
NVS | $94.36 1.93% 0.0% 2.3M
|
Health Technology
|
| O: -1.46%
H: 0.0%
C: 0.0%
PHG | $19.98 0.0% 540K
|
Health Technology
|
| O: -1.21%
H: 0.0%
C: 0.0%
GSK | $39.75 1.22% 0.0% 1.6M
|
Health Technology
|
| O: -1.19%
H: 0.52%
C: -0.17%
VRNA | $15.82 -1.74% -1.83% 640K
|
Health Technology
|
| O: 1.65%
H: 2.43%
C: 0.87%
reach treatment research market
Ocular Therapeutix™ Strengthens Clinical Team with Appointment of Key Retinal Leaders
Published: 2024-04-16 (Crawled : 11:00) - globenewswire.com
NVS | $94.36 1.93% 0.0% 2.3M
|
Health Technology
|
| O: -1.46%
H: 0.0%
C: 0.0%
REGN | $896.27 0.26% 0.25% 500K
|
Health Technology
|
| O: -1.94%
H: 0.43%
C: -0.34%
OCUL | News | $5.22 -10.92% -12.26% 9.1M
|
Health Technology
|
| O: -1.03%
H: 3.66%
C: 1.7%
ocular key leaders
Biologic Therapeutics Market size is set to grow by USD 286.12 billion from 2023-2027, Introduction of biosimilars boost the market, Technavio
Published: 2024-04-15 (Crawled : 22:00) - prnewswire.com
SNYNF | News | $92.7 -2.18% 600K
|
Health Technology
|
| O: -1.75%
H: 0.85%
C: 0.85%
AZNCF | $138.24 -4.19% 800
|
Health Technology
|
| O: 2.1%
H: 0.0%
C: -2.52%
NVS | $94.36 1.93% 0.0% 2.3M
|
Health Technology
|
| O: -1.46%
H: 0.0%
C: 0.0%
GSK | $39.75 1.22% 0.0% 1.6M
|
Health Technology
|
| O: -1.19%
H: 0.52%
C: -0.17%
BAX | $39.47 -0.45% 0.0% 2.8M
|
Health Technology
|
| O: -0.1%
H: 0.13%
C: -1.08%
ABBV | News | $166.41 1.06% 0.0% 5.5M
|
Health Technology
|
| O: 0.32%
H: 0.96%
C: 0.22%
SNY | News | $46.385 2.19% 3M
|
Health Technology
|
| O: -2.13%
H: 0.0%
C: 0.0%
BMRN S | $88.68 -1.54% -1.57% 1.8M
|
Health Technology
|
| O: -0.72%
H: 0.0%
C: 0.0%
AZN | $68.56 0.29% 0.29% 4.7M
|
Health Technology
|
| O: -0.64%
H: 0.45%
C: -0.04%
AMGN | $269.03 2.39% 2.33% 3.4M
|
Health Technology
|
| O: 0.41%
H: 0.0%
C: 0.0%
set therapeutics market
New Novartis Fabhalta® (iptacopan) data show clinically meaningful and statistically significant proteinuria reduction of 38.3% versus placebo for patients with IgA nephropathy (IgAN)
Published: 2024-04-15 (Crawled : 18:00) - globenewswire.com
NVS | $94.36 1.93% 0.0% 2.3M
|
Health Technology
|
| O: -1.46%
H: 0.0%
C: 0.0%
fabhalta nephropathy for novartis show
Gainers vs Losers
| 66% | 34% |
Top 10 Gainers
AGBA | News | $1.305 226.25% 130M
|
Finance
EGOX | $0.0515 43.06% 30.1% 330M
|
OLB 4 | $0.33 -14.95% 25.53% 840K
|
Technology Services
NVFY | $2.77 31.28% 23.83% 33M
|
Consumer Durables
ZCMD | $1.87 28.97% 22.46% 31M
|
Commercial Services
INSG | $3.03 25.21% 330K
|
Electronic Technology
KNW 4 | $0.59 -0.71% 18.64% 27K
|
Manufacturing
GCTK | $0.8191 22.25% 18.2% 190K
|
Manufacturing
WLGS | News | $0.59 18.0% 17.9% 2.3M
|
ASNS | $0.828 21.75% 17.86% 18K
|
Your saved searches
Save your searches and get alerts when important news are released.